| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.066 | 0.7 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |